Do analysts rate CNTB or PYRGF?

Connect Biopharma currently has a consensus price target of $7.17, indicating a potential upside of 191.33%. Given Connect Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Connect Biopharma is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate PYRGF or GNLX?

Genelux has a consensus price target of $18.00, suggesting a potential upside of 502.01%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genelux 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Do analysts prefer NRXP or PYRGF?

NRx Pharmaceuticals currently has a consensus price target of $38.25, indicating a potential upside of 888.37%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe NRx Pharmaceuticals is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NRx Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NRXP or PYRGF more profitable?

NRx Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals N/A N/A -202.92% PyroGenesis Canada -115.14% N/A -60.81%

Do analysts rate COYA or PYRGF?

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 161.66%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend PYRGF or CRDL?

Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 709.52%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than PyroGenesis Canada. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

PyroGenesis Canada (PYRGF) Competitors

$0.14 +0.00 (+0.14%)

As of 07/2/2026 03:51 PM Eastern

Compare

PYRGF vs. CNTB, GNLX, NRXP, COYA, and CRDL

Should you buy PyroGenesis Canada stock or one of its competitors? MarketBeat compares PyroGenesis Canada with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PyroGenesis Canada include Connect Biopharma (CNTB), Genelux (GNLX), NRx Pharmaceuticals (NRXP), Coya Therapeutics (COYA), and Cardiol Therapeutics (CRDL). These companies are all part of the "pharmaceutical products" industry.

How does PyroGenesis Canada compare to Connect Biopharma?

Connect Biopharma (NASDAQ:CNTB) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, earnings, risk, institutional ownership, dividends and valuation.

Connect Biopharma has a beta of -0.23, suggesting that its share price is 123% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

58.7% of Connect Biopharma shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 22.6% of Connect Biopharma shares are held by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Connect Biopharma had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for Connect Biopharma and 0 mentions for PyroGenesis Canada. PyroGenesis Canada's average media sentiment score of 0.00 beat Connect Biopharma's score of -0.17 indicating that PyroGenesis Canada is being referred to more favorably in the news media.

Company	Overall Sentiment
Connect Biopharma	Neutral
PyroGenesis Canada	Neutral

Connect Biopharma currently has a consensus price target of $7.17, indicating a potential upside of 191.33%. Given Connect Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe Connect Biopharma is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Connect Biopharma has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Connect Biopharma	N/A	-122.29%	-97.07%
PyroGenesis Canada	-115.14%	N/A	-60.81%

PyroGenesis Canada has higher revenue and earnings than Connect Biopharma. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Connect Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Connect Biopharma	$60K	2,581.36	-$55.48M	-$1.15	N/A
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A

Summary

Connect Biopharma beats PyroGenesis Canada on 9 of the 17 factors compared between the two stocks.

How does PyroGenesis Canada compare to Genelux?

PyroGenesis Canada (NASDAQ:PYRGF) and Genelux (NASDAQ:GNLX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, media sentiment, risk, dividends and valuation.

In the previous week, Genelux had 4 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for Genelux and 0 mentions for PyroGenesis Canada. Genelux's average media sentiment score of 0.20 beat PyroGenesis Canada's score of 0.00 indicating that Genelux is being referred to more favorably in the news media.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Genelux	Neutral

Genelux has a consensus price target of $18.00, suggesting a potential upside of 502.01%. Given Genelux's stronger consensus rating and higher possible upside, analysts plainly believe Genelux is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Genelux has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Genelux	N/A	-174.55%	-123.65%

0.0% of PyroGenesis Canada shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 47.7% of PyroGenesis Canada shares are held by company insiders. Comparatively, 7.5% of Genelux shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

PyroGenesis Canada has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Genelux has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than Genelux. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Genelux	$10K	13,407.16	-$32.15M	-$0.85	N/A

Summary

Genelux beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

In the previous week, NRx Pharmaceuticals' average media sentiment score of 0.00 equaled PyroGenesis Canada'saverage media sentiment score.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
PyroGenesis Canada	Neutral

NRx Pharmaceuticals has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	N/A	N/A	-202.92%
PyroGenesis Canada	-115.14%	N/A	-60.81%

NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

PyroGenesis Canada has higher revenue and earnings than NRx Pharmaceuticals. PyroGenesis Canada is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	113.99	-$28.62M	-$1.09	N/A
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NRx Pharmaceuticals currently has a consensus price target of $38.25, indicating a potential upside of 888.37%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe NRx Pharmaceuticals is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

NRx Pharmaceuticals beats PyroGenesis Canada on 7 of the 13 factors compared between the two stocks.

How does PyroGenesis Canada compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Coya Therapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for PyroGenesis Canada. Coya Therapeutics' average media sentiment score of 0.50 beat PyroGenesis Canada's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Positive
PyroGenesis Canada	Neutral

Coya Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, PyroGenesis Canada has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

PyroGenesis Canada has a net margin of -115.14% compared to Coya Therapeutics' net margin of -266.10%. PyroGenesis Canada's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
PyroGenesis Canada	-115.14%	N/A	-60.81%

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 161.66%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Coya Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

39.8% of Coya Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PyroGenesis Canada has higher revenue and earnings than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A

Summary

Coya Therapeutics beats PyroGenesis Canada on 9 of the 16 factors compared between the two stocks.

How does PyroGenesis Canada compare to Cardiol Therapeutics?

PyroGenesis Canada (NASDAQ:PYRGF) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

PyroGenesis Canada has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than PyroGenesis Canada, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PyroGenesis Canada	$9.14M	3.56	-$21.12M	-$0.04	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.28	N/A

0.0% of PyroGenesis Canada shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 47.7% of PyroGenesis Canada shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, PyroGenesis Canada's average media sentiment score of 0.00 equaled Cardiol Therapeutics'average media sentiment score.

Company	Overall Sentiment
PyroGenesis Canada	Neutral
Cardiol Therapeutics	Neutral

PyroGenesis Canada has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Cardiol Therapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. PyroGenesis Canada's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PyroGenesis Canada	-115.14%	N/A	-60.81%
Cardiol Therapeutics	N/A	-229.43%	-165.60%

Cardiol Therapeutics has a consensus target price of $8.50, indicating a potential upside of 709.52%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than PyroGenesis Canada.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PyroGenesis Canada	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

PyroGenesis Canada beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

Get PyroGenesis Canada News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYRGF vs. The Competition

Export

Metric	PyroGenesis Canada	Pharmaceutical Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$32.51M	$791.45M	$9.60B	$12.48B
Dividend Yield	N/A	4.84%	3.53%	6.52%
P/E Ratio	-2.41	1.66	27.03	24.70
Price / Sales	3.56	127.11	4,750.02	99.42
Price / Cash	N/A	20.06	27.49	57.09
Price / Book	-14.44	8.17	4.60	6.46
Net Income	-$21.12M	-$3.71M	$791.01M	$337.01M
7 Day Performance	-0.14%	2.59%	0.96%	1.69%
1 Month Performance	-17.95%	4.41%	0.95%	3.81%
1 Year Performance	-57.64%	49.43%	18.47%	23.90%

PyroGenesis Canada Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYRGF PyroGenesis Canada	N/A	$0.14 +0.1%	N/A	-57.6%	$32.51M	$9.14M	N/A	90	Gap Up
CNTB Connect Biopharma	4.5067 of 5 stars	$2.21 +6.5%	$7.17 +225.0%	+116.7%	$130.34M	$233K	N/A	110	Analyst Downgrade Gap Up High Trading Volume
GNLX Genelux	1.895 of 5 stars	$2.87 -0.9%	$18.00 +526.5%	+0.3%	$130.04M	$10K	N/A	10	News Coverage High Trading Volume
NRXP NRx Pharmaceuticals	2.2582 of 5 stars	$3.73 +4.8%	$38.25 +925.5%	+16.9%	$128.98M	$2.29M	N/A	2
COYA Coya Therapeutics	2.3879 of 5 stars	$5.50 +7.2%	$15.33 +178.8%	-6.5%	$120.33M	$7.95M	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYRGF) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. CNTB, GNLX, NRXP, COYA, and CRDL

How does PyroGenesis Canada compare to Connect Biopharma?

Summary

How does PyroGenesis Canada compare to Genelux?

Summary

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

Summary

How does PyroGenesis Canada compare to Coya Therapeutics?

Summary

How does PyroGenesis Canada compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PyroGenesis Canada (PYRGF) Competitors

PYRGF vs. CNTB, GNLX, NRXP, COYA, and CRDL

How does PyroGenesis Canada compare to Connect Biopharma?

Which has more risk and volatility, CNTB or PYRGF?

Do insiders & institutionals believe in CNTB or PYRGF?

Does the media prefer CNTB or PYRGF?

Do analysts rate CNTB or PYRGF?

Is CNTB or PYRGF more profitable?

Which has better valuation and earnings, CNTB or PYRGF?

Summary

How does PyroGenesis Canada compare to Genelux?

Does the media refer more to PYRGF or GNLX?

Do analysts rate PYRGF or GNLX?

Is PYRGF or GNLX more profitable?

Do institutionals & insiders have more ownership in PYRGF or GNLX?

Which has more risk & volatility, PYRGF or GNLX?

Which has better earnings and valuation, PYRGF or GNLX?

Summary

How does PyroGenesis Canada compare to NRx Pharmaceuticals?

Does the media prefer NRXP or PYRGF?

Is NRXP or PYRGF more profitable?

Which has more risk & volatility, NRXP or PYRGF?

Which has stronger earnings & valuation, NRXP or PYRGF?

Do institutionals and insiders believe in NRXP or PYRGF?

Do analysts prefer NRXP or PYRGF?

Summary

How does PyroGenesis Canada compare to Coya Therapeutics?

Does the media refer more to COYA or PYRGF?

Which has more risk & volatility, COYA or PYRGF?

Is COYA or PYRGF more profitable?

Do analysts rate COYA or PYRGF?

Do institutionals & insiders believe in COYA or PYRGF?

Which has stronger valuation and earnings, COYA or PYRGF?

Summary

How does PyroGenesis Canada compare to Cardiol Therapeutics?

Which has stronger earnings and valuation, PYRGF or CRDL?

Do institutionals and insiders believe in PYRGF or CRDL?

Does the media favor PYRGF or CRDL?

Which has more risk and volatility, PYRGF or CRDL?

Is PYRGF or CRDL more profitable?

Do analysts recommend PYRGF or CRDL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYRGF vs. The Competition

PyroGenesis Canada Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools